SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following a surprise CEO change and a Q4 earnings miss combined with weak 2026 guidance, prompting a fierce debate among investors who are split between calling it "PainPal" facing permanent decline and a "generational buying opportunity" at historically low valuations.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amidst a substantial price drop, driving community discussion around significant unrealized losses for major holders like MicroStrategy and widespread predictions of further declines; a controversial narrative linking the cryptocurrency to disreputable figures is also actively circulating and cited by some users as a reason for its current downturn.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following an early earnings release that, despite a Q4 beat, included a significant 2026 guidance cut, triggering a sharp sell-off and stock halt. The community is actively debating whether this reflects intentional manipulation or an overreaction, with many highlighting strong early sales of the Wegovy pill and a new share repurchase program as reasons for optimism.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is trending as a significant drop in Bitcoin's price has intensified community debate surrounding the company's aggressive crypto acquisition strategy. Investors are weighing liquidation fears and continued share dilution against upcoming earnings and the potential for a long-term recovery for the Bitcoin-centric firm.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending lower amid escalating geopolitical tensions following a US military action involving an Iranian drone, with community discussion also highlighting broad tech and software sector weakness driven by fears of AI automation and mixed corporate earnings reports.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp ($BULL) is plummeting to new all-time lows, fueling intense investor frustration over management's perceived silence and ongoing concerns about potential dilution from a Yorkville agreement. Aggressive shorts are celebrating easy gains, while long-term holders lament significant losses amidst broader fintech sector pressures, with some still citing fundamental undervaluation.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant stock price decline, with the community largely attributing the downturn to aggressive short selling and broader market rotation out of small-cap AI names, despite the company's reported strong fundamentals and upcoming earnings. Investors are expressing frustration over perceived manipulation while many remain long-term bullish, actively dollar-cost averaging and anticipating a rebound.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing a significant downturn, driven by immediate concerns over the US losing its lead in open-source AI, echoed by prominent tech CEOs, which is sparking widespread community discussions about a "bloodbath" in tech and testing crucial support levels.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors grapple with its upcoming Q4 earnings report, debating whether global social media bans for youth and the strategic spin-off of its AR glasses division will prove to be a catalyst for a rebound or deepen concerns over its path to profitability. Community sentiment is sharply divided, with some seeing an undervalued buying opportunity at multi-year lows, while others criticize management and fear further declines.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending amidst community concerns that the CFTC's stance on prediction markets, classifying them as financial contracts rather than gambling, could create an unregulated competitive threat with tax advantages. This, combined with weak betting data from key states, is driving investor frustration over the stock's significant and continuous decline, overshadowing traditional pre-Super Bowl optimism.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ENSC Great Science- CEO has not purchased a share with her own money and terrible at keeping company funded!!!! very sad for shareholders. one day it will rerate but probably after mgt buy shares!!!! sad sad story 
dyor- huge potential but keeps dropping for years

ThereAre4Lights

mrsparex

StockTwits Web

Ensysce Biosciences Inc

 Great Science- CEO has not purchased a share with her own money and terrible at keeping company funded!!!! very sad for shareholders. one day it will rerate but probably after mgt buy shares!!!! sad sad story 
dyor- huge potential but keeps dropping for years

BULLISH1975

@BULLISH1975 glad to see you&#39;re still here... so am i, but i&#39;m willing to take the short term pain (lol) to put the screws to management.

 glad to see you're still here... so am i, but i'm willing to take the short term pain (lol) to put the screws to management.

@BULLISH1975 and you&#39;re right, there is literally ZERO reason management shouldn&#39;t be buying at these levels. they&#39;re &quot;about&quot; to start phase 3... unless they know what&#39;s gonna happen next and screw everyone for a THIRD time. gonna buy the pump then short the top, need to make some money back. also, BS news release, &quot;yes... i finished half of my homework, give me money&quot; whoopty fucking do, pathetic attempt to drum up interest... nobody in their right mind would do that looking at the chart

 and you're right, there is literally ZERO reason management shouldn't be buying at these levels. they're "about" to start phase 3... unless they know what's gonna happen next and screw everyone for a THIRD time. gonna buy the pump then short the top, need to make some money back. also, BS news release, "yes... i finished half of my homework, give me money" whoopty fucking do, pathetic attempt to drum up interest... nobody in their right mind would do that looking at the chart

@ThereAre4Lights this has been a terrible investment buddy! i do think it will be a 100 million MC in 2027 but what happens until then.  unbelievably no insiders buying. one day if starts going and carries on but this mgt has failed so badly so far imo

 this has been a terrible investment buddy! i do think it will be a 100 million MC in 2027 but what happens until then.  unbelievably no insiders buying. one day if starts going and carries on but this mgt has failed so badly so far imo

@BULLISH1975 I am not worried about some CEO buying shares.  I am sure he owns enough shares already.  I just know that their drug is legit and when it gets approved and it will, this will be a 50 dollar stock or more one day.  I am not concerned about some price target at 20 dollars.  This drug is a game changer and all the doctors will prescribe this

 I am not worried about some CEO buying shares.  I am sure he owns enough shares already.  I just know that their drug is legit and when it gets approved and it will, this will be a 50 dollar stock or more one day.  I am not concerned about some price target at 20 dollars.  This drug is a game changer and all the doctors will prescribe this

BJ Dietrich

@BULLISH1975 So Denise according to the last filing with this information was making 400k plus a 50% bonus. Add in the other exec team members and this is pretty much where the money is going. Nice gig… It’s the reason why they keep doing offerings and RS and why they don’t own stock.  The shares are worthless and they know it.  I’m guessing the feds finally woke up and asked where is the money going since it took them almost a year to enroll 1 person. Now they changed CRO’s and poof they are at 50%. They probably time another offering and RS to float them for another year. Doubtful they get another grant.  However the lack of any longterm institutional ownership or financing tells you what the market thinks. Anson only counts if you like to short.

StockTwits for iOS

 So Denise according to the last filing with this information was making 400k plus a 50% bonus. Add in the other exec team members and this is pretty much where the money is going. Nice gig… It’s the reason why they keep doing offerings and RS and why they don’t own stock.  The shares are worthless and they know it.  I’m guessing the feds finally woke up and asked where is the money going since it took them almost a year to enroll 1 person. Now they changed CRO’s and poof they are at 50%. They probably time another offering and RS to float them for another year. Doubtful they get another grant.  However the lack of any longterm institutional ownership or financing tells you what the market thinks. Anson only counts if you like to short.